RxDoctor Payments Data

Amanda Ribbeck, MD

Interventional Cardiology · Amherst, NYNPI 1417214271

Payments from drug & device makers

$9,514in general payments, 2019–2025

Across 436 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bridgebio Pharma, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$534
  • Alnylam Pharmaceuticals Inc.$494
  • Novartis$480
  • AstraZeneca$477
  • Boehringer Ingelheim$411
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$1,10812%
  • Food & beverage$8,26087%
  • Education$1462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,514 in reported general payments places this provider in the 45th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$316,796
Medicare patients
1,008
Services billed
3,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban918$1,246,091
VyndamaxTafamidis28$818,279
Repatha SureclickEvolocumab454$472,430
XareltoRivaroxaban290$396,018
EntrestoSacubitril/Valsartan264$361,752
JardianceEmpagliflozin99$139,916
Praluent PenAlirocumab85$67,914
FarxigaDapagliflozin Propanediol58$61,170
MultaqDronedarone Hcl29$50,053
Metoprolol Succinate1,519$31,943
CorlanorIvabradine Hcl27$27,832
NexlizetBempedoic Acid/Ezetimibe22$22,729
Rosuvastatin Calcium958$19,802
Dabigatran EtexilateDabigatran Etexilate Mesylate56$17,862
Repatha SyringeEvolocumab14$14,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$329$2,064,370946 claims
Johnson & JohnsonXarelto$289$396,018290 claims
NovartisEntresto$480$361,752264 claims
Boehringer IngelheimJardiance$411$139,91699 claims
AstraZenecaFarxiga, Brilinta$477$73,64077 claims
Sanofi-aventis U.S. LLCMultaq$225$50,05329 claims
AmgenCorlanor$331$27,83227 claims
Esperion Therapeutics, Inc.Nexlizet$197$22,72922 claims
Novo NordiskWegovy$209$13,85511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →